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ABSTRACT: 
Once a magnetic resonance spectroscopy (MRS) dataset has been acquired, several 
important steps must be taken to obtain the desired metabolite concentration measures.  
First, the data must be preprocessed to prepare them for analysis. Next, the intensity of the 
metabolite signal(s) of interest must be estimated. Finally, the measured metabolite signal 
intensities must be converted into scaled concentration units employing a quantitative 
reference signal to allow meaningful interpretation. In this paper, we will review these three 
main steps in the post-acquisition workflow of a single-voxel MRS experiment (preprocessing, 
analysis and quantification) and provide recommendations for best practices at each step. 
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Introduction 
The goal of an in vivo MRS experiment is to estimate the relative or absolute concentrations 
of tissue metabolites within a specific anatomical region of interest. Once the time domain 
MRS data have been acquired, several steps are needed in order to get meaningful and 
reliable concentration estimates. First a series of preprocessing steps should be applied to 
prepare the spectrum for analysis. Next, analysis of the processed dataset is performed, often 
by peak fitting, to estimate the metabolite signal intensities. Finally, the unitless signal 
intensity measures are converted into scaled concentration estimates, a process we refer to 
here as quantification, to enable meaningful interpretation and comparisons of tissue 
metabolite levels between subjects and groups, regardless of the site of acquisition or other 
measurement conditions. Each of these three steps is critically important; errors in any of 
them can reduce the reliability of, or completely invalidate, the obtained metabolite 
concentration measures.  
 
In this article, we focus on these three important steps in the workflow of single-voxel 1H-MRS 
following data acquisition: preprocessing, spectral analysis; and quantification. We describe 
some of the most important and commonly used approaches in each step, and provide 
recommendations for best practices (see Tables for all recommendations). Finally, we list 
common pitfalls in the post-acquisition workflow and suggest ways to avoid them. Though the 
emphasis in this article will be on single-voxel 1H-MRS, with attention to the challenges of its 
application in the brain, many of the general principles of the post-acquisition workflow apply 
to MRS data obtained from other nuclei, other regions of the anatomy, and MR spectroscopic 
imaging (MRSI) data.  For more information regarding MRSI specific processing and analysis 
methods, the reader is referred to the article on MRSI in this special issue by Maudsley et al1. 
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Preprocessing 
Preprocessing of MRS data, sometimes also simply called “processing”, describes any 
operation, or series of operations, that is applied to the acquired raw MRS data (free induction 
decays, FIDs) to prepare them for analysis. There are three main reasons for preprocessing 
in MRS. First, MRS data are unavoidably degraded by experimental imperfections (e.g. eddy 
currents, scanner drift, subject motion). Since spectral fitting models generally do not take all 
of these imperfections into account, some preprocessing operations are needed to remove 
the imperfections, to the extent possible, in advance. Second, raw data are almost always 
multi-dimensional, with multiple acquired signal averages by multiple coil channels from 
parallel receive array coils. Thus, some preprocessing is needed to combine these signals 
and reduce the data into a (usually) one-dimensional spectrum that can be analyzed.  Finally, 
some other preprocessing operations, such as Fourier transformation, phasing, apodization 
and zero-filling, are not strictly related to data quality, but can be used to aid in visual 
interpretation or peak fitting performance. 
 
Note that several of the preprocessing routines described below require access to the 
individual averages or transients, stored independently for each receiver channel. 
Accordingly, we strongly recommend the use of data formats in which the individual transients 
and individual receiver channels are preserved. At present, each MRI vendor has its own 
unique data formats, and each format differs in regards to which dimensions are preserved 
and which have been collapsed (implying some ‘online’ preprocessing, See Table 1 below).  
The lack of cross-vendor standardization in terms of MRS data formats and online 
preprocessing strategies can be a source of confusion, and represents a major unmet need in 
the MRS community2. 
 
Preprocessing operations to remove/correct spectral imperfections 
 
Correction of eddy current effects 
 
Rapid gradient switching gives rise to unwanted short-lived fluctuation of the B0-field, called 
eddy current effects, which can persist for hundreds of milliseconds after a gradient switching 
event. If the acquisition window occurs close to the end of a gradient pulse, a multi-
exponential decaying B0-field component may exist during the early part of the acquisition 
window, giving rise to a time-dependence in the resonance frequencies of the acquired FID. 
This unwanted effect distorts spectral line shapes and can severely impact the robustness of 
further spectral analysis.  
 
The most common method of dealing with this issue involves collecting an unsuppressed 
water spectrum, centred on the water resonance, using identical gradient strengths and 
timings as in the water suppressed dataset3. Any time-dependence in the frequency of the 
water signal will be observed as a non-linearity in the phase of the FID signal. Since this 
phase function essentially describes the time-dependence of the field offset observed in both 
water-suppressed and water-unsuppressed scans, the correction involves simply subtracting 
this phase function from both the water-suppressed and water-unsuppressed FID signals. 
This simple approach is remarkably effective in most cases, and results in FID signals that 
are essentially free of residual eddy current effects. Related methods exist for correcting eddy 
current effects while simultaneously restoring purely Lorentzian line shapes by applying both 
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Subject motion has pronounced effects on spectral quality. Despite all efforts to control 
subject motion, some small amount of motion is practically inevitable in the timeframe of an 
MRS scan. One practical way to test for gross motion is to acquire a quick localizer image 
immediately before and after the MRS scan and compare the position of the anatomy of 
interest between those two scans. Better yet, the collection of rapid navigator images 
between each repetition6-11, or optical tracking12,13 can be used to precisely monitor subject 
motion, and even update the acquisition volume in real time to compensate. Although highly 
promising, these prospective motion correction strategies for 1H-MRS are not yet in 
mainstream use, and thus retrospective correction methods are commonly employed. 
 
Very small amounts of motion, for example due to normal physiological motion (breathing, 
cardiac pulsation, swallowing) or small bulk movements of less than a few millimetres, have a 
minor effect on spectral quality and are therefore relatively benign in most cases. These 
minute motions result in small changes in the frequency and phase of the individual transients 
which can easily be corrected by a retrospective frequency and phase drift correction (see 
below). In the case of large amounts of motion such as gross motion of the head or limbs, 
much larger spectral distortions are observed14. Moreover, severe gross motion can lead to 
unwanted sampling of tissue outside the region of interest. In this case, it may be necessary 
to either remove the transients that are most severely affected by motion15, or to discard the 
dataset altogether. To assess motion severity in a quantitative and unbiased way, signal 
reliability tests have been proposed16. An example of the removal of motion corrupted 
transients is illustrated in Figure 2a.  
 
 
Retrospective removal of frequency and phase drifts 
 
The main magnetic field of an MRI scanner, B0, is subject to subtle temporal drift (often called 
scanner drift), due to heating and cooling of the ferromagnetic passive shim elements, which 
are in thermal contact with the gradient coils17. As a result, frequency drifts are observed 
during the course of most MRS experiments. The magnitude of these drifts can vary greatly 
from scanner to scanner and is also affected by use of gradient-intensive pulse sequences 
before the MRS scan, but normally ranges between 1-10 Hz of total drift during the course of 
a typical MRS acquisition (i.e. 2-10 minutes). Moreover, as mentioned above, physiological 
motion or small bulk motion during the MRS scan leads to additional frequency and phase 
offsets, independent of scanner drift. If not corrected, these frequency and phase drifts will 
lead to broadening of spectral peaks, reduction in signal-to-noise ratio (SNR), and line shape 
distortion. 
 
Several methods exist for retrospective correction of frequency and phase drifts. Some 
involve tracking the frequency and phase of the residual water peak to estimate and correct 
the frequency and phase drifts11,18-21, while others make use of separately acquired navigator 
echoes22. If a residual water peak or navigator echoes are not available for frequency and 
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phase estimation, individual metabolite peaks can also be used23. More recently, methods 
such as spectral registration24, RATS25 or other variants26,27 have been proposed and involve 
alignment of each transient, in either the frequency domain or the time domain, to a reference 
spectrum for estimation and correction of the frequency and phase offsets. The advantage of 
these latter methods is that they make use of the full spectrum to perform the correction, and 
do not rely on the presence of any one particular resonance. Most algorithms optimize the 
frequency and phase in a single step, rather than sequentially. An example of retrospective 
frequency and phase drift correction is illustrated in Figure 2b.  In some cases, an online 
frequency drift correction may be employed by the scanner software.  While the use of such 
online corrections is recommended, it may be advantageous to apply an additional 
retrospective drift correction offline, since online corrections may correct frequency, but not 
phase drifts.  
 
Frequency and phase drift correction methods that rely on internal signals for alignment will 
inevitably fail if the SNR of the individual transients is low (for example if the voxel is very 
small). In such cases, one can average successive groups of 4-8 transients to improve SNR, 
and then apply a drift correction to the resulting series. Alternatively, a method called 
metabolite cycling28-31 has been proposed in which the water peak is not suppressed, but the 
magnetization of the metabolites is inverted on every other acquisition. In this way, the high-
SNR water peak can be used for drift correction, even if the metabolite SNR is low. When the 




Alignment and subtraction of sub-spectra 
 
1H-MRS pulse sequences involving subtraction are increasingly common. Some examples 
include J-difference editing sequences such as MEGA-PRESS32 and HERMES33; or the 
SPECIAL sequence34, which uses subtraction to achieve localization. If the sub-spectra in 
these acquisitions are not properly aligned prior to subtraction, the resulting difference 
spectrum may be corrupted by unwanted subtraction artefacts that can impact quantification.  
 
Alignment of subtraction sub-spectra can be performed using the same techniques that are 
used for removal of frequency and phase drift in conventional spectra (e.g. spectral 
registration, etc.)35,36. However, if subtraction sub-spectra are vastly different in appearance, 
conventional alignment procedures may not perform well, and dedicated routines may be 
required for optimal alignment. Dedicated alignment algorithms have previously been 
proposed for MEGA-PRESS37,38, HERMES39, and SPECIAL15. 
 
Substantial frequency drift during J-difference edited acquisitions results in reduced editing 
efficiency, due to offsets in the frequency of the highly selective editing pulses.  This effect is 
not corrected by retrospective alignment of the subtraction sub-spectra.  Instead, drift-related 
reductions in editing efficiency must be addressed at the level of the acquisition (using real 
time frequency updating10), or in the analysis (by accounting for drift-related editing efficiency 
losses in the basis set40).  For more information on this topic, the reader is referred to the 
article on spectral editing in this special issue by Choi et al41. 
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Nuisance peak removal (residual water, lipids, spurious echoes) 
 
In vivo 1H-MRS acquisitions are specifically designed to suppress nuisance signals such as 
water and outer volume signal. However, perfect suppression is challenging, as the signals to 
be suppressed are usually orders of magnitude larger than the signals of interest. As a result, 
noticeable contamination of spectra is a relatively common occurrence, especially in 
challenging brain regions (regions very close to the scalp, or regions with poor B0 
homogeneity), and minimizing signal contamination is an important aspect of data 
preprocessing.  Note that even though nuisance signals can sometimes be addressed via 
processing strategies, it is always preferable to remove these contaminating signals at the 
level of the acquisition. 
 
Poor water suppression can be handled in two ways. Residual water signal can be removed 
prior to spectral analysis by fitting the peak to a line shape function – usually either Gaussian, 
Lorentzian, or Voigt (combination of Gaussian and Lorentzian) – or to a series of line shape 
components via singular value decomposition, and then subtracting the resulting fit from the 
spectrum42,43. Another approach is to not remove the water peak, but to perform analysis 
using a fitting model that incorporates a water peak (or the sloping baseline that results from 
the residual water peak). Lipid contamination, like poor water suppression, can impact 
spectral quantification and can be dealt with in a similar manner, with the main difference 
being that contaminating lipid peaks are generally much broader than residual water peaks 
and often overlap with metabolites of interest, often making lipid contamination more difficult 
to correct. 
 
Spurious echoes are another commonly observed nuisance signal in in vivo 1H-MRS. These 
are typically caused by unwanted coherence pathways and often originate from tissues 
outside the region of interest. The issue of unspoiled coherences is best dealt with by 
modifications to the acquisition, such as changing the timing or amplitudes of the spoiler 
gradients, improving B0 homogeneity, or improving the phase cycling scheme14,44. A few 
preprocessing approaches have been proposed to identify and remove spurious echoes 
based on filtering, or deep learning45, but these methods are still relatively new and may 
require further development before being deployed widely.  Spurious echoes may occur near 
the end of an FID, in which case apodization can be used to greatly reduce their appearance; 
but users should analyze the resulting data with caution, since apodization is not 
recommended before spectral analysis (see Apodization section below).  An example of 
commonly observed spurious echoes is shown in Figure 3. 
 
Recommendations for the preprocessing operations to remove/correct spectral imperfections 
are listed in Table 2. 
 
 
Preprocessing operations to reduce dimensionality  
 
RF coil combination 
 
Most modern MRI systems are equipped with highly parallel RF receiver arrays, sometimes 
with as many as 64 or even 128 elements in close proximity to the head. Each of the receiver 
elements will detect different signal and noise amplitudes as well as a different signal phase 
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offset that will depend on the voxel location and head position relative to the coil element. 
Combining the signals from the various coil elements should be done in such a way that 
maximizes the SNR of the resulting spectrum. In all cases, this requires 1) adjusting the 
phase of each channel so that all elements are phase coherent; and 2) applying an amplitude 
weighting to each channel for optimal SNR combination. The RF channels with the strongest 
signals are given the highest weighting, while the RF channels with the weakest signals are 
given the lowest weighting46,47. The amplitude, phase and noise terms necessary for coil 





Signal averaging is the process of taking the average of the acquired transients (the sum of 
all transients divided by the number of transients) to produce a resultant spectrum with 
increased SNR. The convention of averaging transients ensures that the signal remains 
constant, while noise is reduced (subjectively); thus, subsequent quantification of signal 
intensity in “averaged” spectra requires no consideration of the number of transients. Despite 
the fact that the arithmetic mean is by far the most common approach for combining 
transients, some authors have proposed taking the median of the acquired transients as an 
alternative approach, suggesting that the median is more robust against temporal instabilities 
in the signal16. 
 








Conversion of the discrete time-domain FID signal into a spectrum is performed using a 
discrete Fourier transformation such as the fast Fourier transform (FFT).  Most software 
programming languages offer a built-in implementation of the FFT, and all MRS software 
packages will perform the Fourier transformation by default.  To convert from the spectral 





Whereas MRI signal intensities are generally displayed as the magnitude of the complex 
signal intensity at each voxel, it is most common in MRS to display the real part of the 
complex signal, to avoid unwanted spectral broadening.  As a result, the spectral appearance 
is greatly influenced by the phase of the complex spectral points, which depends on many 
factors including cable lengths, receiver phase, RF pulse phase, voxel position, pulse 
sequence timing, etc. In most cases, an “in-phase” spectrum is one in which the prominent 
singlet peaks display an absorption line shape, meaning that they are upright and symmetric 
(assuming minimal eddy current artefacts). Some spectral analyses may require that the 
spectrum first be “in-phase”, but many common analysis packages either perform an 
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automatic phasing step prior to fitting, or include phase as a fitting parameter, so it is often not 
necessary for the user to perform this step in advance.   
 
Phase correction involves either adding a constant phase to each point in the spectrum (zero-
order phasing), or adding a linear phase shift as a function of frequency (first-order phasing), 
until the spectrum appears “in-phase”. Manual zero- and first-order phasing is a common 
approach, however, identifying a correctly phased spectrum takes practice and can be 





Apodization is a procedure aimed at attenuating the noise in an MR spectrum, while 
preserving the signals of interest. Conveniently, the signals of interest are strongest at the 
beginning of the FID signal in the time domain, whereas the later part of the FID is mostly 
noise. Thus, by applying an apodization function in the time domain which gives a higher 
weight to the early timepoints and a lower weight to the later timepoints, the desired effect is 
achieved. Apodization also minimizes truncation artefacts that occur due to incomplete FID 
decay during the acquisition window. Common apodization functions include an exponential 
or Gaussian decay. Although apodization reduces noise and generally improves SNR, it also 
has some unwanted consequences, such as broadening/distortion of spectral line shapes. As 
a result, apodization can have significant impact on analysis and quantification results, and is 





The digital resolution of an MR spectrum (frequency spacing between adjacent spectral 
samples) is given by 1/Tacq, where Tacq is the duration of the acquired FID signal. Thus, if the 
acquisition duration is especially short, the resulting spectrum may have limited digital 
resolution. This problem can be addressed by zero-filling (sometimes called zero-padding) 
whereby a train of zeros is added to the end of the FID signal. This artificially lengthens the 
FID (increases the value of Tacq) and therefore increases the digital resolution of the 
spectrum, without adding any additional noise. However, it’s important to realize that this 
operation amounts to an interpolation operation in the frequency domain and does not 
improve the actual resolution of the spectral peaks.  For this reason, zero-filling before 
spectral analysis is not recommended. Nonetheless, zero-filling can be useful for visualization 
and display purposes, or for improving the stability of certain other operations such as 
evaluation of peak height, peak frequency, or linewidth. 
 
Recommendations for other preprocessing operations are listed in Table 4. 
 
Figure 4 shows two preprocessing pipelines; one that includes only basic steps to combine 
the coils and transients (similar to the standard preprocessing pipelines provided by clinical 
scanner vendors), and a second involving additional steps to remove motion corrupted 
averages, to retrospectively correct frequency and phase drift, and to remove eddy current 
artefacts. When the same dataset is processed separately through these two pipelines, the 
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resulting differences in spectral quality are apparent, highlighting the importance of removing 
motion corrupted scans and correcting frequency and phase drift. 
 
Following preprocessing, the user must judge whether the quality of the final processed 
spectrum is sufficient for meaningful analysis and quantification. This judgement should 
incorporate objective measures of spectral quality (linewidth and SNR), but may ultimately 
require consideration of factors that are difficult to quantify objectively, such as the presence 
of artefacts or nuisance signals.  Recent advances in machine learning techniques have 
made it possible to objectively assess all of the above aspects of spectral quality in an 
automated fashion51-53, thereby avoiding any potential user bias associated with visual 
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Analysis 
After preprocessing, the spectrum is ready for the next stage: spectral analysis. The goal of 
spectral analysis is to estimate the spectral peak areas (or equivalently, time-domain signal 
amplitudes) of the various metabolites of interest in the spectrum, as well as that of some 
reference signal. At this stage, the units of measurement are not important: only the relative 
raw signal intensities are needed. These will be converted to meaningful concentration units 
in the next stage (quantification). In this section, we will briefly summarize the process of 
spectral analysis and provide some basic recommendations. 
 
The three most common ways of estimating MRS peak areas are 1) linear combination model 
fitting, 2) peak fitting, and 3) peak integration. 
 
 
Linear combination model fitting 
 
In linear combination model fitting, each metabolite’s contribution to the overall spectrum is 
modelled as a single response function called a ‘basis spectrum’. The basis spectrum 
describes an individual metabolite’s full spectral contribution, and can be obtained either by 
phantom experiment54 or by numerical simulation15,55-59. A major advantage of using basis 
spectra over individual peak components is that it greatly reduces the total number of model 
functions required to fully model the spectrum, resulting in fewer parameters to fit, and a 
corresponding reduction in the Cramér-Rao minimum variance bound (CRMVB) estimates 
(the most commonly used measure of the uncertainty of the model fit parameter estimates). 
Moreover, since basis spectra are generated directly from experiment or simulation, they are 
physically realistic, and can be highly accurate. Once the full set of metabolite basis spectra 
(the basis set) is produced, a constrained non-linear least-squares analysis can be used to fit 
a linear combination of the basis spectra to the acquired MR spectrum by adjusting their 
individual amplitudes and frequencies.  Additional global terms such as spectral phase and 
linewidth are normally included to improve the fit, thus necessitating the non-linear least-
squares approach.  The relative amplitudes (or weights) of the various metabolite basis 
spectra in the best fit correspond to the estimated relative signal intensities.  The fit residual – 
the difference between the fit and the data – provides an indicator of the goodness of fit, or 
the presence of unmodelled peaks in the spectrum.  Quantitatively, this can be expressed 
using the fit quality number (FQN) which is the ratio of the variance in the fit residual divided 
by the variance in the pure spectral noise60.  For an ideal fit, the FQN should be close to 1.0, 
and the FQN/SNR ratio should be << 1.  Some examples of linear combination model fitting 
are shown in Figure 6. 
 
Linear combination model fitting is the most popular method of analysis and is recommended 
for most in vivo MRS applications. Several software packages provide implementations of this 
approach, including LCModel54, Tarquin61, Vespa55, FiTAID62, INSPECTOR63, and jMRUI64. 
This approach is well-suited to analysis of crowded MRS data, such as short echo-time 1H-
MRS of the human brain, but can also be used to fit more sparse spectra, including long TE 
spectra and J-difference edited data. Linear combination model fitting allows for the inclusion 
of broad macromolecular components, as well as baseline components (often a “model-free” 
spline function) to account for any remaining broad, unmodeled background signal 
contributions as described below. Since the unmodeled baseline components are poorly 
characterized by definition, these baseline estimates often represent the greatest source of 
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uncertainty in fitting models. For example, the knot spacing of the spline function can be 
chosen by the user, but the choice is fairly arbitrary and can have a significant impact on 





Rather than using basis spectra to model each metabolite’s full spectral contribution, it is 
possible to select individual peaks of interest within a spectrum, and to fit each using a simple 
line shape model function. This involves choosing a line shape model that best describes the 
peaks of interest and fitting each spectral peak of interest to the model function. Common line 
shape functions include Gaussian, Lorentzian and Voigt. Fitting is achieved through 
adjustment of multiple model parameters including the amplitude, phase, frequency offset, 
linewidth, and baseline offset of each model function (or of all model functions, globally); 
however, the main parameter of interest is the amplitude, which scales in direct proportion to 
concentration. For metabolites with multiple resonances, prior knowledge of the fixed relative 
amplitudes, phases and frequencies of the various peaks can (and should) be used to 
constrain the fits and improve the results. This is the method employed by the AMARES66 
technique, which is built into the popular MRS software package jMRUI64,67. However, in 
crowded spectra such as 1H-MRS of the brain, the amount of prior knowledge quickly 
becomes overwhelming due to the large number of metabolites and the large number of 
peaks per metabolite. Therefore, like peak integration (see below), this method is most 
commonly used in applications involving relatively sparse MRS data such as long TE, or J-
difference edited brain MRS68,69, 31P MRS70 or 13C MRS71. Compared with peak integration, 
peak fitting is less sensitive to baseline contamination, especially if a baseline offset 
parameter is included in the fit. 
 
 
Modelling of macromolecule and baseline signal 
 
Underlying the signals of the handful of detectable small molecules (metabolites) in tissue, 
are signals from many larger MR visible molecules (proteins, mobile lipids, etc). These larger 
molecules are often called macromolecules (MM), and are characterized by short T2 
relaxation, resulting in broad spectral components that underlie the signals of interest. 
Because the specific molecular origins of these signals are poorly characterized, modelling of 
MM signals is difficult, and necessarily empirical in nature. But if not accounted for, MM 
contamination will cause metabolite concentrations to be overestimated, particularly in short 
echo-time 1H-MRS data.  Because of their relatively rapid T2 relaxation, MM components can 
be omitted from the model when fitting data acquired at very long echo times (see Table 5 for 
recommended TE thresholds for omitting MM). 
 
There are various ways to account for MM contributions. One common approach is to include 
parametrized models of the most prominent macromolecular signals as components in the 
spectral fitting model72,73. Another common approach is to directly acquire the 
macromolecular signals using a metabolite-nulled (single or double) inversion recovery 
sequence74,75. Once measured directly, this MM component can either be subtracted from the 
metabolite spectrum prior to analysis76,77 or included as a component in the spectral fit78. 
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Figure 5 shows an example of the typical signal contribution from MM in short echo-time 
MRS, and its modeling via individual parametrized components. 
 
Even after nuisance signals and MM components have been removed from the spectrum as 
described above, the spectral baseline still may not appear perfectly flat. The remaining 
baseline arises from any unmodeled signal sources, including the long tail of an 
unsuppressed water peak, additional unmodeled macromolecular components, or outer 
volume contamination. These baseline signals should be removed prior to spectral analysis or 
included in the fitting model to avoid biasing metabolite concentration estimates. This baseline 
signal can be estimated directly from the acquired MRS data either using time domain 
approaches that assume very early decay79, or by frequency domain methods which attempt 
to model the baseline as a spline function54. In any case, it is difficult to separate the baseline 
from the metabolite signals; and as a result, this is one of the largest sources of uncertainty in 
in vivo MRS quantification.  For further details on state-of-the-art of MM modeling and 
baseline signal correction, the reader is referred to the experts’ recommendations article on 





Peak integration estimates a metabolite’s signal intensity by calculating the area under its 
peak in the frequency domain81. This is done by choosing a frequency range around the 
centre of the (well-phased) peak of interest, and summing the discrete spectral points within 
that range. When quantifying multiple peaks in the same spectrum, it is important to ensure 
that the width of the integration range is the same for all peaks82. Although strictly speaking, 
spectral peaks have infinite extent in the frequency domain, it is generally sufficient to ensure 
that the integration range is at least twice the full-width at half maximum (FWHM) of the 
broadest peak. If a spectrum is sparse with few overlapping peaks, peak integration can be 
robust. However, if the spectrum contains multiple overlapping peaks, peak integration cannot 
effectively estimate their individual contributions. Similarly, peak integrals will be biased by the 
presence of baseline contributions, and are unreliable for multiplet groups whose net area is 
close to zero (e.g. anti-phase coherences). Therefore, peak integration is only recommended 
for MRS data with very sparse (non-overlapping), well-phased peaks and no baseline or 
macromolecule contribution (e.g. 1H-MRS with TE>150 ms, or 13C spectra). 
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Quantification: From Signals to Concentrations 
Converting 1H-MRS signals from the brain into metabolite concentrations entails comparing 
the metabolite signals to either an internal or external chemical concentration reference or to 
an externally synthesized signal. The internal references used are either the tissue water 
signal or an individual signal (or combination of signals) within the metabolite spectrum. The 
most common external standard consists of water or a chemical of known concentration in a 
solution either positioned close to the subject’s head during the scan or scanned before or 
after the subject (‘phantom replacement’). Less commonly, an RF signal is artificially injected 
during the MRS sequence detection period, using either an external antenna or a scanner RF 
coil (ERETIC83, although this method is not yet available from any of the major scanner 
vendors).  
 
When referenced to other metabolite signals, metabolite levels are usually reported simply as 
a ratio to the reference metabolite (either an intensity ratio or a concentration ratio, the 
distinction being that the latter is corrected for the number of protons per peak, while the 
former is not) and not corrected for relaxation or partial volume effects. When referenced to a 
known concentration standard corrected for partial volume and relaxation effects, 
concentrations are reported in terms of “absolute” concentrations, using either molar (moles/L 
of tissue), or molal units (moles/kg of tissue water).  Units of moles per kg of tissue are also 
sometimes used and are closely related to molar units, but are not further discussed here. 
Alternatively, “institutional units” are often used to report relative concentration levels, making 
limited corrections for relaxation or claims to be the actual concentrations.  As described in 
more detail below, our main recommendation is to use molar or molal units over institutional 
units; and importantly, whatever concentration units are used, it should be explicitly stated in 
any publication of the findings.   
 
Though a survey of the MRS literature may reveal that molarity is reported more often than 
molality, both are equally valid ways of reporting concentration.  Regardless of which unit is 
used, the difference between them is important to understand when comparing results across 
studies.  
 
In chemistry, molarity is the number of moles of solute (metabolite) per volume of solution 
(tissue). When comparing a metabolite signal from tissue to a water or chemical signal from 
an external solution of known molar concentration, the appropriate units are molarity. 
However, when using tissue water as a reference, either molarity or molality can be used. In 
the case of molarity, the tissue volume sampled (excluding cerebrospinal fluid (CSF)) is 
considered to be the volume of the “solution.”  That is, the solution is the tissue water (the 
solvent) along with all the other components of the tissue, excluding CSF. To account for the 
fact that the water signal arises from only a fraction of the solution volume, the concentration 
of water in the tissue is estimated by scaling the concentration of pure water by the assumed 
tissue water density, which differs in grey matter (GM) and white matter (WM). Molality, on the 
other hand, is simply based on how much solute (metabolite) is present in a mass of solvent 
(the tissue water), and thus may relate more closely to the chemical concentration (i.e. 
intracellular concentration). As will be shown in the following section, if the MRS signals are 
not acquired under fully relaxed conditions, the tissue densities also need to be taken into 
account to properly scale for relaxation attenuation in different compartments when estimating 
either molarity or molality. 
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Tissue water  
 
The most commonly used reference for estimating metabolite concentrations is the tissue 
water signal84-87. An advantage of using the water signal is that it arises from essentially the 
same volume of tissue as the metabolite when the same pulse sequence is used to acquire 
the metabolite signals. This ensures that the RF calibration and homogeneity, excitation 
profile and receiver sensitivity at the location of the metabolite and water acquisitions are 
identical. This is approximately the case for single-voxel 1H-MRS if the chemical shift 
displacement is minimized.  
 
The cellular environments of the metabolites are complex and varied, with different water, 
macromolecule and lipid densities, and other factors affecting signal relaxation and detection. 
To make the problem tractable, the first assumption generally made is that the various 
metabolite compartments can be approximated as gray matter (GM), white matter (WM), 
cerebrospinal fluid (CSF), and, possibly, pathological tissue (e.g. MRI-visible lesions), with 
uniform physical properties within each of these pools, including across cellular and 
extracellular sub-compartments. The different tissue and CSF fractions are determined by 
segmentation of an MR-image to which the MRS voxel has been registered. It is worth noting 
that different MRI segmentation methods generally give slightly different results, and there is 
no ‘gold standard’ to establish their relative accuracy88.  
 
In a simple solution, the 1H-MRS signal from a solute (or from the solvent) is directly 
proportional to the number of moles of the solute (or of solvent) in the sampled voxel, scaled 
by any relaxation attenuation and instrumental factors (see Alger paper89  for a 
comprehensive review). In the complex milieu of brain tissue, it is usually assumed that all of 
the molecules of a metabolite of interest are contributing to the measured signal. This implies 
that the molecules are mobile enough to have a relatively long transverse relaxation time (T2), 
and hence relatively narrow spectral peak(s). When correcting a multi-peak metabolite signal 
for relaxation, it is often (but not always) assumed that the signals from distinct protons on the 
molecule, aside from any exchangeable ones, have the same T2 and longitudinal relaxation 
time (T1). 
 
For the case of fully relaxed water and metabolite proton signals acquired identically from the 





Moles of metabolite × 𝑁𝑀
Moles of water × 2  
[1] 
 
where 𝑆𝑀 and 𝑆𝐻2𝑂 are the metabolite and water proton signal intensities, respectively, 𝑁𝑀 is 
the number of metabolite protons contributing to 𝑆𝑀 and 2 is the number of water protons 
contributing to 𝑆𝐻2𝑂. In the case of linear combination model fitting, the number of protons (𝑁𝑀 
and the factor of 2 in the denominator) can safely be ignored here and in the equations that 
follow, since these values are encoded in the relative amplitudes of the peaks in the basis 
spectra. 
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To convert the signal ratio in Eq. [1] to units of concentration, we divide both mole factors by 
either the mass of the solvent (tissue water) for molal concentrations or liters of solution (total 













where [𝐻2𝑂]molal is the molal concentration of pure water or 55.51 moles/Kg, the inverse of its 
molecular weight (18.015x103 Kg/mole, https://pubchem.ncbi.nlm.nih.gov/compound/Water).  
 
If molar concentration is to be estimated, the total volume of sampled tissue needs to be 
considered rather than just the volume of tissue water. In order to account for the fact that the 
water signal arises from only a fraction of the tissue volume, the molar concentration of tissue 
water is estimated by scaling the molar concentration of pure water by the tissue water 
density, which differs in GM and WM. Again assuming a voxel with pure tissue (no CSF), the 












where 𝑑𝐺𝑀 and 𝑑𝑊𝑀 refer to the tissue-specific water content, defined as the MR visible water 
volume fraction in either GM or WM (see Appendix I, supplementary materials) and 𝑓𝐺𝑀 and 
𝑓𝑊𝑀 are the volume fractions of GM and WM in the voxel, and [H2O]molar is approximately 
55.01 moles/L at 37 ⁰C and 1 bar of pressure. Values for water content in healthy human 
brain tissue have been drawn from various reports85, but it is well to keep in mind that, 
regardless of the source, one set of water density values may not be appropriate for the entire 
brain nor for pathological tissue90. In particular, in WM it should be considered whether and to 
what degree the short-T2 pool of myelin water91 of up to 15% is contributing to the water 
reference signal85. 
 
If the voxel contains CSF, the water concentration in Eq. [2] is divided by the tissue water 
mole fraction in the voxel (𝑓𝐺𝑀𝐻2𝑂 + 𝑓𝑊𝑀𝐻2𝑂or equivalently 1 − 𝑓𝐶𝑆𝐹𝐻2𝑂, where 𝑓𝐶𝑆𝐹𝐻2𝑂  is the 
CSF water mole fraction). Similarly, [𝑀]molar in Eq. [3] needs to be scaled by the volume 
fraction of tissue (𝑓𝐺𝑀 + 𝑓𝑊𝑀, or equivalently 1 − 𝑓𝐶𝑆𝐹, where 𝑓𝐶𝑆𝐹 is the CSF volume fraction), 
and the term multiplying the signal ratio becomes (𝑓𝐺𝑀𝑑𝐺𝑀 + 𝑓𝑊𝑀𝑑𝑊𝑀 + 𝑓𝐶𝑆𝐹𝑑𝐶𝑆𝐹  ). CSF is 
generally devoid of detectable metabolites in healthy brain other than glucose (3-5 mM), 
lactate (~2 mM)92,93 and glutamine (0.4-0.8 mM)94,95, and the contributions of even these 
metabolites are usually assumed to be insignificant if care is taken to minimize the fraction of 
CSF in the voxel (e.g. 𝑓𝐶𝑆𝐹<0.2). 
 
Taking into consideration the effect of signal relaxation leads to the final modifications of the 
fundamental equations [2] and [3]. If the data were not acquired under fully relaxed 
conditions, the observed signals, 𝑆𝑀𝑜𝑏𝑠 and 𝑆𝐻2𝑂𝑜𝑏𝑠, need to be divided by appropriate 
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relaxation factors. In the case of a typical double spin echo (e.g. PRESS) or stimulated echo 
experiment (e.g. STEAM) with TR >> TE, the form of the relaxation scaling factors is 𝑅 =
 𝑒𝑥𝑝[−TE/𝑇2](1− 𝑒𝑥𝑝[−TR/𝑇1]), where the relaxation times are those of either the metabolite 
or the water protons. If TR is not much greater than TE, the factor is 𝑅 =  𝑒𝑥𝑝[−TE/𝑇2](1 −
 2𝑒𝑥𝑝[−(TR − TE1/2)/𝑇1]  +  2𝑒𝑥𝑝[−(TR− TE1 −  TE2/2)/𝑇1]  −  𝑒𝑥𝑝[−TR/𝑇1])96,97 where TE1 
and TE2 are the first and second echo times within the double-echo pulse sequence.  
 
Water proton signals relax at different rates in GM, WM, and CSF, as do metabolite proton 
signals in GM and WM. The differences are large for water, spanning a factor of nearly 10 
from WM to CSF. However, they are comparatively small for metabolites in GM and WM, 
such that the metabolite relaxation times can be approximated as the average of their GM 
and WM times without adding a large error to the concentration estimate98. Accounting for 
tissue-specific water relaxation as well as a partial volume correction for CSF leads to the 
following expression for molal concentration88: 
 
[𝑀]molal =
𝑆𝑀𝑜𝑏𝑠 × �𝑓𝐺𝑀𝐻2𝑂𝑅𝐻2𝑂𝐺𝑀 + 𝑓𝑊𝑀𝐻2𝑂𝑅𝐻2𝑂𝑊𝑀 + 𝑓𝐶𝑆𝐹𝐻2𝑂𝑅𝐻2𝑂𝐶𝑆𝐹�






where the relaxation scaling factors 𝑅𝐻2𝑂𝑥 refer to the factors for water protons in GM, WM, or 
CSF, and the term 𝑅𝑀 refers to the relaxation scaling factor for metabolite protons assuming 
average GM-WM relaxation times or, in the case of voxels with CSF and only GM or only 
WM, the metabolite relaxations times appropriate to either tissue. 
 
As noted above, the fractions appearing in this equation are the tissue and CSF water mole 
fractions. They are related to the tissue volume fractions (obtained by image segmentation) 




𝑓𝐺𝑀𝑑𝐺𝑀 + 𝑓𝑊𝑀𝑑𝑊𝑀 + 𝑓𝐶𝑆𝐹𝑑𝐶𝑆𝐹
 [5] 
 
where ‘𝑥’ in the subscript refers to GM, WM or CSF.  Converting from tissue volume to tissue 
water mole fractions using Eq. [5] relies on assumptions of water density, often assumed to 
be: 𝑑𝐺𝑀 = 0.78, 𝑑𝑊𝑀 = 0.65 and 𝑑𝐶𝑆𝐹 = 0.9785.  
 
An equation similar to Eq. [4] can be derived for molar concentrations98,99: 
 
[𝑀]molar =
𝑆𝑀𝑜𝑏𝑠 × �𝑓𝐺𝑀𝑑𝐺𝑀𝑅𝐻2𝑂𝐺𝑀 + 𝑓𝑊𝑀𝑑𝑊𝑀𝑅𝐻2𝑂𝑊𝑀 + 𝑓𝐶𝑆𝐹𝑑𝐶𝑆𝐹𝑅𝐻2𝑂𝐶𝑆𝐹�







Eqs. [4] and [6] can be further modified using Eq. 7 below to include tissue-specific (GM and 
WM) relaxation scaling factors for metabolites98: 
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𝑅𝑀𝐺𝑀_𝑊𝑀 =
𝑓𝐺𝑀𝑑𝐺𝑀 × ([𝑀]𝐺𝑀 [𝑀]𝑊𝑀⁄ ) × 𝑅𝑀𝐺𝑀 + 𝑓𝑊𝑀𝑑𝑊𝑀𝑅𝑀𝑊𝑀
𝑓𝐺𝑀𝑑𝐺𝑀 × ([𝑀]𝐺𝑀 [𝑀]𝑊𝑀⁄ ) + 𝑓𝑊𝑀𝑑𝑊𝑀
 [7] 
 
This term introduces an extra unknown factor [𝑀]𝐺𝑀 [𝑀]𝑊𝑀⁄ , i.e., the ratio of the GM to the 
WM metabolite concentrations, which is not known a priori. The ratio arises from the need to 
know what fraction of the total metabolite signal is to be weighted by 𝑅𝑀𝐺𝑀  and what fraction 
by 𝑅𝑀𝑊𝑀 . For a detailed derivation of the above quantification formulae, the reader is referred 
to Appendix I (supplementary materials).   
 
Using Eqs. [4] and [7] with simulated 3 T data and assuming metabolite ratios from previous 
studies, it was shown that the errors that arise from not correcting for tissue-specific 
metabolite relaxation in mixed-tissue voxels will be less than 8% for NAA when assuming 
typical TRs and TEs, reported GM and WM metabolite relaxation times, and a hypothetical 
GM/WM NAA ratio of 1.298. For example, maximum errors of 7.8% in concentrations resulted 
when TR = 1.5 s and TE = 144 ms, but were reduced to 1.6% when TR =3 s and TE= 6 ms 
and to less than 0.5% when TR = 6 s and TE = 6 ms. The maximum errors occur when the 
tissue-averaged relaxation times are used instead of the tissue-specific relaxation times to 
“correct” the relaxation attenuation when the voxel actually contains only pure GM or pure 
WM.  Eq.[7] can be used to examine the possible errors arising in any other scenario. 
 
To minimize such errors, accurate estimates of tissue-specific metabolite relaxation times, 
when available, should be used to correct for relaxation attenuation in voxels with mixtures of 
GM and WM. It is worth noting, however, that metabolite relaxation times are very challenging 
to measure, even for metabolites with relatively high SNR, and are simply not practical to 
perform for all metabolites of interest, nor in every region of the brain or on a study-to-study 
basis. Furthermore, both water and tissue relaxation times are field-dependent and brain 
metabolite relaxation times have been reported to vary with age100-102.  
 
In lieu of accurate relaxation time estimates, long TR (TR>>T1) and short TE (TE<<T2) should 
be considered to reduce relaxation attenuation when possible, as illustrated in the case of 
NAA shown above. However, the TE used in a study is often determined by the specific pulse 
sequence applied, which depends on the goals of the study (e.g. spectral editing or otherwise 
optimizing detection of particular signals, reduction of high field artefacts with adiabatic 
pulses, etc.). Moreover, the TR needs to be short enough (usually ≤ 3 s) to be practical for 
human studies. If a long TR and short TE are not possible, ensuring that the MRS voxel 
contains mostly GM or mostly WM and using the metabolite relaxation times appropriate to 
that tissue will be the best option for reducing errors due to inaccurate relaxation times.  
 
The recommendations for reducing errors related to inaccurate metabolite relaxation time 
estimates also apply to inaccuracies in the estimates of the water signal relaxation times. 
Long TRs and short TEs reduce the effect of these inaccuracies. A field-independent T1 of 
approximately 4 s has been reported for CSF water protons103, so the CSF water signal will 
still be appreciably attenuated even at a TR of 3 s. Therefore, care should be taken to 
minimize the fraction of CSF in the voxel to reduce the CSF water signal contribution. 
Additionally, it is worth noting that if molal concentrations are estimated, the impact of 
inaccurate assumptions about the tissue water densities are reduced at long TR and short 
TE, vanishing as the relaxation factors in Eq. [4] approach a value of 1.  
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Given the challenges for accurate 1H-MRS concentration estimates in the brain, it is not 
surprising that some researchers opt for reporting “institutional units”, making no claim to be 
the actual concentration. Such units are fine when comparing different groups within a study, 
given the caveats on the interpretation of the results noted above. However, attempting to 
estimate the actual concentrations facilitates the comparison of results across studies and 
field strengths, essential for meta-analyses. Due to the challenges discussed above, 
particularly the unknown variation of water density and signal relaxation with pathology, this 
will be difficult to realize in practice. However, if MRS is ever to be used as a routine clinical 
exam, similar to a blood test, concentration estimates based on some standard protocol 





In principle, using either the water signal or another metabolite signal within the spectrum as a 
concentration reference are both ‘ratio’ methods. The water signal is about 104 times larger 
than the metabolite signals and is uncomplicated by overlap with other signals, whereas any 
metabolite reference is, by comparison, very weak and has to be resolved from its spectral 
neighbors. Furthermore, it is not possible to minimize the chemical shift displacement error 
inherent across the spectrum by changing the excitation frequency of the reference signal, as 
in tissue water referencing.  However, a reference signal from within the metabolite spectrum 
(from either a single or a sum of metabolites), shares the other benefits of tissue water as a 
reference: it is inherently corrected for transmit RF field (B1) and receiver inhomogeneity, 
magnetic field drift, and other instrumental factors. Additionally, a metabolite reference has 
two advantages over tissue water: 1) no extra scan is needed to obtain it and 2) it obviates 
the need to correct the results for CSF inclusion in the voxel, since, as noted previously, other 
than lactate and glucose, the metabolites in CSF are generally below the levels of detection 
by in vivo 1H-MRS if care is taken to minimize its inclusion in the voxel.  
 
An important factor to consider when using metabolite ratios is confidence in the stability of 
the reference across age, gender, pathology, or other factors. As noted earlier, while the 
concentration of pure water does not change (molarity does change with temperature and 
pressure, molality does not), the tissue water density, in fact, may change with pathology or 
other factors104. Similarly, the metabolite signals typically used as references, such as those 
from the total creatine (tCr=Cr+PCr), total choline (tCho=GPC+PCh) or total NAA 
(tNAA=NAA+NAAG), are also subject to change with age78,105-107 and pathology108-111.  
 
The majority of studies reporting metabolite ratios use the tCr signal as the reference, with the 
results given as the values of the ratio and not as concentrations. The latter option would 
require an assumption about the concentration of tCr which, in fact, would need to take into 
consideration its very different concentrations in GM and WM (GM [tCr] is nearly double WM 
[tCr]). Along these lines, generally no correction is made for GM and WM partial volume 
effects nor tissue-specific relaxation effects. Hence, metabolite ratios, while circumventing the 
needs for CSF partial volume correction and a separate acquisition to measure the reference 
(as is done for water referencing), are not concentration estimates, per se. They are 
conveniently acquired markers of metabolic differences, their interpretation subject to 
assumptions regarding which part of the ratio is changing, if not both, and in which direction. 
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The most common approach to referencing the metabolites of the brain to an external 
reference involves scanning a spherical ‘phantom’ solution containing a particular 
concentration of the reference chemical after scanning the brain (phantom replacement or 
reciprocity principle)112,113. Less commonly, a phantom solution is located next to the subject’s 
head during the scan. Either method requires correcting the signals for differences in RF 
power (coil loading and B1 inhomogeneity) and/or receiver sensitivity between the phantom 
and brain voxel locations, introducing possible instrumental sources of error. Notably, 
variations in B1 homogeneity are more likely at high B0 field strength, largely limiting its use to 
3 T and below. In addition to these, of course, one must still be concerned about partial 
volume and signal relaxation corrections, as discussed for internal standards, if accurate 





Electric REference To access In vivo Concentrations (ERETIC) entails the synthesis of a 
calibrated RF signal close in frequency to the metabolite signals and detected either along 
with metabolite signals83,114,115 or in a separate experiment116. The synthesized signal is 
broadcast either by a scanner coil or an external antenna83,116 or it is directly inductively 
coupled to the receiver coil114,115. The signal is calibrated with a water phantom with similar 
size and dielectric properties as the head. However, unlike using the phantom directly as a 
reference for the metabolite signal, the synthesized signal does not dielectrically load the 1H 
receiver coil and, hence, does not need to be corrected for different loading. Transmit RF (B1) 
inhomogeneity and receiver sensitivity differences between the brain and phantom 
acquisitions, however, still need to be measured and accounted for in the calculation of 
concentrations, as does the phase of the synthesized signal and the temperature difference 
between the phantom and brain115. Currently, the development of ERETIC has been limited to 
single-voxel studies. The need for accurate partial volume and relaxation corrections, as 
when using tissue water as an internal reference, remain. Three different studies have shown 
that ERETIC measurements of brain metabolites compare well with those based on tissue 
water as a concentration reference114-116. 
 
Recommendations for absolute quantification are listed in Table 6 below: 
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In conclusion, preprocessing, analysis and quantification are the three main steps in the post-
acquisition MRS workflow.  Each of these steps is challenging, and requires careful thought 
and planning in order to achieve the end goal of obtaining reliable quantitative measures of 
tissue chemistry. It is hoped that the guidelines and recommendations provided here will 
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Figure 1.  Eddy current correction in synthetic 3T human brain PRESS spectra with TE=30 
ms.  In the top panel, water reference (left) and water suppressed (right) spectra with eddy 
current artefacts are shown.  The central panel shows the phase evolution of the water 
reference FID before eddy current correction.  Any deviation from linearity in this phase 
function is the result of the eddy current effect.  The bottom panel shows the same water 
reference (left) and water suppressed (right) spectra following eddy current correction.   
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Figure 2. Removal of corrupted transients and retrospective frequency and phase drift 
correction from a 3T human brain PRESS acquisition with TE=270 ms.  Removal of motion 
corrupted transients is shown in the top panel (a).  Corrupted transients stand out as 
noticeably different from the others, and are effectively removed using an unsupervised 
outlier removal procedure (see Ref. 15).  Subsequent retrospective frequency and phase 
drift correction is shown in the bottom panel (b).  Following drift correction using spectral 
registration, the individual transients have improved coherence and can now be averaged.  
These processing steps yield a marked improvement in both the FWHM and SNR of the final 
averaged spectrum 
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Figure 3. Examples of spurious echoes in 3 T human brain MRS data (TE=68 ms).  In the 
top panel, minor spurious echoes are observed in the individual transients around 1.8 ppm 
and 4.3 ppm.  However, following averaging of the phase cycled scans, these are effectively 
removed, so that this spectrum can be safely analyzed.  In the bottom panel, severe 
spurious echoes are observed in the individual transients between 3.5-4.6 ppm.  Even after 
combining these phase cycled averages, visible contamination remains (e.g. overall jagged 
character of the spectrum between 3.6-4.4 ppm, distortion of the glutamate-H2 doublet at 
3.75 ppm, and distortion of the myo-inositol peak at 4.1 ppm), and this spectrum should 
therefore be discarded. 
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Figure 4. Illustration of two example processing pipelines, applied to the same raw data.  
The dataset was obtained from a rat brain using the PRESS sequence at 7 T with TE=11 
ms.  Processing pipeline B (dark red boxes, right side) includes only basic steps to combine 
the coils and transients (similar to the standard processing pipeline provided by clinical 
scanner vendors).  Processing pipeline A (green boxes, left side) involves additional steps to 
remove motion corrupted averages, to retrospectively correct frequency and phase drift, and 
to remove eddy current artefacts. Pipeline A resulted in several noticeable improvements in 
spectral quality, including reduced water contamination (orange arrows), and improved visual 
definition of most spectral peaks, including lactate (1.3 ppm, dark blue arrows), glutamate-H4 
(2.3 ppm, purple arrows), tCho (3.2 ppm, light blue arrows), taurine (3.4 ppm, red arrows),  
and myo-inositol (3.5 ppm, pink arrows). These improvements highlight the importance of 
using an appropriate processing pipeline.  Note that as stated in the recommendations 
tables, zero-filling and apodization may be used to improve the visual appearance of the 
spectrum, but should not be performed prior to spectral analysis. 
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Figure 5. Macromolecule estimation in short-TE MRS.  The top trace (blue) shows a 3 T MR 
spectrum from a human subject using the SPECIAL sequence with TE=8.5 ms.  The second 
trace from the top (black) shows the metabolite-nulled MM spectrum from the same 
individual and voxel position, obtained using the same pulse sequence, but with an inversion 
recovery preparation.  The third trace from top (dark red) illustrates a simple model fit of the 
above MM spectrum using 8 individual Lorentzian components.  The 8 individual 
components of the modelled MM spectrum fit are shown in the bottom traces. 
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Figure 6. Two examples of linear combination model fitting are shown.  In both cases the 
acquired data are displayed at the top in dark red, the overall fit is displayed second from the 
top in green, and the fit residual is displayed third from the top in dark blue.  Below the fit 
residual, the individual metabolite fit components are displayed in black.  The example on 
the left is from a 3 T human brain PRESS spectrum with TE=68 ms. The example on the 
right is from a 3 T human brain MEGA-PRESS difference edited spectrum with TE=68 ms.  
Note the small peaks around 3.0 ppm in the MEGA-PRESS fit residual, indicating imperfect 
modelling of the GABA signal due to MM contamination. 
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Tables 








GE p-file P01234.7 Np x Ntra/Npc -By default, RF coil channels pre-combined online; and groups of 
Npc phase cycle steps pre-combined online. The resulting number of 
separately stored transients is Ntra/Npc. 
-However, the p-file can be customized to preserve or combine 
any/all dimensions. 
-Both water and metabolite data can may be stored within the same 
series. 
Philips data/list filename.data 
filename.list 
 
Np x Ntra -Water and metabolite data are normally stored in separate files, 
but some pulse sequences may store both within the same series.    
-Depending on settings, water unsuppressed transients may be 
interleaved within groups of water suppressed transients, and 
frequency drift correction may have been applied. 
-Two files for each acquisition: .data file contains the acquired 




Np x Ntra/Npc -Separate files for water and metabolite data. 
-Two files for each acquisition:  .sdat file contains the acquired 
signal data; .spar file contains header info. 
Siemens Twix filename.dat Np x NRF x Ntra -All dimensions (RF channels, transients) are preserved without 
modification. 
- Water and metabolite data are normally stored in separate files, 
but some pulse sequences may store both within the same series.  
rda filename.rda Np -By default, all dimensions (except time/spectral dimension) are 
pre-combined online. 
-However, .rda files can be customized to preserve or combine 
any/all dimensions. 
- Water and metabolite data are normally stored in separate files, 
but some pulse sequences may store both within the same series.  
.ima filename.ima 
Np 
-By default all dimensions (except time/spectral dimension) are pre-
combined online. 
-However, .ima files can be customized to preserve or combine 
any/all dimensions.  In this case, each individual transient is stored 
in a separate .ima file.  
- Water and metabolite data are normally stored in separate files, 
but some pulse sequences may store both within the same series.  
Bruker fid-file fid Np -All dimensions (except time/spectral dimension) are pre-combined 
online. 




(Up to PV 5) 
 
Np x Ntra -RF channels are pre-combined online. 
-All transients are preserved without modification. 
-Separate files for water and metabolite data. 
job0 file rawdata.job0 
(PV 6 and 
later) 
Np x Ntra -RF channels are pre-combined online. 
-All transients are preserved without modification. 
-Separate files for water and metabolite data. 
Varian/ 
Agilent 
Fid file Fid Np x NRF x Ntra -Full flexibility to preserve or collapse all dimensions.   




DICOM Various e.g.: 
filename.dcm 
Np -By default, all dimensions are collapsed. 
-However, dicom files can be customized to preserve or combine 
any/all dimensions.  In this case, each individual transient may be 
stored in a separate dicom file.   
-Separate files for water and metabolite data. 
Np = number of points in the FID 
NRF = number of RF channels 
Ntra = number of transients 
Npc = number of phase encoding steps in one phase cycle 
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Table 2.  Recommendations for preprocessing operations to remove/correct spectral 
imperfections. 
Name of operation Recommendation 
Eddy current 
correction 
- An eddy current correction should be applied routinely during the preprocessing of any in 
vivo MRS dataset. 
- For accurate eddy current estimation, the unsuppressed water scan must be collected 
from the same voxel location and using the exact same gradient scheme as the water 
suppressed data (e.g. turn only water suppression RF pulses off for unsuppressed water 
acquisition.) 
- Some analysis software packages (LCModel54, Tarquin61, FiTAID62) perform an eddy 
current correction at the analysis stage, obviating the need to perform this step in 
advance. 
 
Motion correction - For small amounts of motion, correct the resulting frequency and phase jitter using a 
frequency and phase drift correction (see below). 
- More severe bulk motion is indicated by individual transients that stand out as 
significantly different from the rest. Identify these “corrupted” transients either by visual 
inspection or by unsupervised outlier detection, and remove them prior to analysis. 
- If more than ~30% of the acquired transients are corrupted by motion, we recommend 
discarding that particular dataset since a) the likelihood of significant unwanted sampling 
of tissue outside the region of interest is high, and b) the continued removal of transients 
has a detrimental effect on the final SNR.   
 
Frequency and 
phase drift correction 
- Frequency and phase drift correction should be applied routinely for in vivo MRS, 
provided that there is enough SNR in the individual (or a few summed) transients to 
achieve robust frequency and phase estimation. 
- There are many effective methods for retrospective frequency and phase drift correction. 
We recommend methods that make use of the full spectrum (unless a weakly suppressed 
water peak is used for alignment).  
-Where available, the use of vendor-provided online drift corrections is recommended, 
provided that their performance has been well-validated; but offline retrospective drift 





- Subtraction-based MRS techniques should always be coupled with an appropriate 
alignment procedure to align sub-spectra prior to subtraction. The choice of alignment 
procedure depends on the acquisition method.  
- In J-difference edited MRS, retrospective alignment of subtraction sub-spectra does not 




- It is always preferable to remove nuisance signals at the level of the acquisition, rather 
than via preprocessing. 
- If necessary, large water and lipid signals can either be removed prior to analysis, or 
accounted for in the analysis model.  Alternatively, one can adjust the frequency range 
over which spectral analysis is performed, in order to avoid nuisance signals.   
- Spurious echoes should be identified by visual inspection. 
- Since processing methods to remove spurious echoes are not widely available, we 
recommend that spectra contaminated by large spurious echoes should be discarded from 
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Table 3.  Recommendations for preprocessing operations to reduce dimensionality. 
Name of operation Recommendation 
RF coil combination - Most vendors provide a data output option in which an acceptable RF coil combination 
has already been performed. 
- However, if the raw data is provided with coils uncombined, the user must perform coil 
combination. 
- Coil combination should include appropriate complex weights (phase and amplitude). 
- Complex weights should be determined using an unsuppressed water scan. 
- The amplitude weighting should be generally determined by signal/noise2 as per Hall et 
al.46, although more sophisticated approaches may yield improved results for certain coil 
designs and voxel locations. 
 
Signal averaging - We recommend combining transients using the arithmetic mean (the sum of all transients 
divided by the number of transients).  Although less robust to instabilities across transients 
than the median, we suggest dealing with these instabilities through removal of motion 
corrupted averages and frequency/phase drift correction prior to averaging. 
-If motion corrupted transients have been removed, divide only by the number of 
transients that were retained.   
- Avoid combining averages using the simple sum of the acquired transients (i.e., the sum 
should always be divided by the number of transients). 
- Likewise, subtraction operations used in difference spectroscopy should also be treated 
as an averaging operation, i.e., when subtracting sub-spectra of a MEGA-PRESS 
difference editing experiment or a SPECIAL localization experiment, the difference 
spectrum should always be divided by 2 (the number of transients involved in the 




Table 4. Expert recommendations for other processing operations. 
Name of operation Recommendation 
Fourier tansformation - An implementation of a discrete Fourier transformation, such as the fast Fourier 
transform (FFT) should be used to convert the time-domain FID signal into a spectrum.   
- Conversion from the spectral domain back to the time domain should be performed using 
the inverse discrete Fourier transform.   
 
Phasing - Some common data analysis packages perform an automated phasing step prior to 
fitting, so it is often not necessary to perform a phasing step in advance of spectral 
analysis.   
- Phasing should generally be performed prior to displaying or inspecting a spectrum to 
enable easy visual interpretation.  
- Both manual and automated phasing routines are equally acceptable, but, visual 
verification of automatic phasing results is recommended.  
 
Apodization - Apodization can be useful for visualization purposes. 
- Not recommended to apodize data prior to spectral analysis – this can invalidate 
statistical assumptions associated with the fitting model.  
 
Zero-filling - Zero-filling before spectral analysis is not recommended. 
- May be helpful prior to some other processing routines such as peak fitting for linewidth 
estimation or center frequency estimation. 
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Table 5.  Recommendations for spectral analysis. 




- Generally recommended due to its proven effectiveness, versatility and relative ease of 
use. 
- Ensure accuracy of the basis set: 
a) for experimental basis sets derived from phantoms, the phantom temperature 
and pH, and the phantom acquisition parameters (pulse sequence, field strength, 
TE, etc.) should match the in vivo acquisition;  
b) for simulated basis sets, the simulation parameters should match the in vivo 
acquisition (pulse sequence, field strength, echo time, and optionally the RF pulse 
shapes and durations). 
c) simulations should use reliable estimates of chemical shifts and coupling 
constants of each metabolite spin system117-119. 
- Always visually inspect the quality of the fit. A good fit should have small fit residuals 
which mostly appears like noise. 
- Compute the Cramér-Rao minimum variance bounds (CRMVB), which are estimators of 
the minimum uncertainties in the estimated parameters (assuming that the model is 
complete and accurate. In particular the estimated errors would not apply if baseline 
estimation or phasing is done separately from actual modeling).   
- Metabolite measures of individual subjects should not be excluded based on high relative 
uncertainties (% CRMVB).  Instead, individual subjects may be excluded on the basis of 
high absolute CRMVB values.   
- If the average %CRMVB for a metabolite is consistently high (>30%) across all subjects, 
consider excluding that metabolite from the reported results across the entire subject 
cohort.   
- Estimated baseline should be smooth, without fine structure or sharp peaks. 
- The number of protons per metabolite spin system is automatically encoded within the 
simulated or acquired basis set. Therefore, when using linear combination model fitting, 
the number of protons does NOT need to be considered in quantification (see 
quantification section). 
 
Handling MM and 
baseline 
contributions 
- MM fitting and baseline correction are generally required, but MM components can be 
omitted for long echo-time data (TE ≥ 150 ms at 3 T; TE ≥ 100 ms at 7 T;  TE ≥ 100 ms at 
9.4 T in rodent brain). 
- MM resonances should be removed or accounted for by including them as components 
in the analysis model. 
- Ideally, MM models should be based on an acquired MM spectrum. 
- Even with nuisance peak removal and MM modelling, an additional baseline correction 
should be performed.  Use either time domain methods that assume rapid decay of 
baseline components, or frequency domain methods that assume a spline baseline. 
 
Peak fitting and peak 
integration 
- Recommended only in cases where  
a) the spectrum is sparse (contains relatively few peaks), and  
b) MM and baseline contribution are minimal, or have been removed in 
preprocessing. 
- Spectrum must be properly phased prior to peak integration.  
- Peak fitting requires that spectral peaks can be approximated by simple line shape 
functions.  Peak integration does not have this requirement.  
- When using peak fitting or peak integration the number of protons per metabolite peak 
does need to be considered in quantification (see quantification section).  
- In case of peak fitting, always visually inspect the quality of the fit. A good fit should have 
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- Comparing metabolite signals to tissue water within the same region of interest, and 
calculating concentrations in either molarity or molality is the most robust and technically 
straightforward approach to ‘absolute’ quantification.  
- Whatever concentrations are used, it must be explicitly stated in any publication of the 
findings; preferably along with the specific quantification formulae that were used as well all 
assumed parameter values, so that the reader can fully reproduce the quantification method.  
 
TE and TR - While short TEs and long TRs are not an option for many pulse sequences, if absolute 
concentration estimates are a goal of the study, pulse sequences capable of very short TEs, 
such as STEAM120 or SPECIAL29, could be considered;  
- If short TE (<10 ms) and/or long TR (> 4 s) is not possible, measured or literature values of 
the metabolite and water relaxation constants (T1, T2) should be used in quantification.   
- All assumed values for relaxation constants, tissue water densities, etc. must be reported, 
so that others may compare results.   
 
ERETIC - The ERETIC method, while promising, is not yet widely available. We encourage scanner 
manufacturers to develop ERETIC referencing capabilities into their products, which we 
believe would be an important step towards reliable absolute quantification on clinical 
systems.  
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List of abbreviations 
Abbreviation Meaning 
MRS Magnetic resonance spectroscopy 
1H Proton 
MRSI Magnetic resonance spectroscopic imaging 
FID Free induction decay 
RF Radiofrequency 
NP Number of points in FID/spectrum 
NRF Number of radiofrequency channels 
Ntra Number of transients 
Npc Number of phase encoding steps in one phase cycle 
B0 The main magnetic field 
𝜙(𝑡) Phase function of the water FID 
SNR Signal-to-noise ratio 
MEGA-PRESS Mescher-Garwood Point Resolved Spectroscopy 
HERMES Hadarmard Encoding and Reconstruction of Mega Edited 
Spectroscopy 
SPECIAL Spin Echo full Intensity Acquired Localized spectroscopy 
MM Macromolecules 
T2 Transverse (spin-spin) relaxation time constant 
TE Echo time 
MRI Magnetic resonance imaging 
Tacq Duration of the acquired free induction decay 
FWHM Full width at half maximum 
13C Carbon-13 
CRMVB Cramér-Rao minimum variance bounds 
FQN Fit quality number 
ERETIC Electric REference To access In vivo Concentrations 
GM Grey matter 
WM White matter 
CSF Cerebrospinal fluid 
T1 Longitudinal (spin-lattice) relaxation time constant 
𝑆𝑀 Metabolite signal intensity 
𝑆𝐻2𝑂 Water signal intensity 
𝑁𝑀 Number of protons contributing to metabolite signal  
[𝑀]molal Metabolite concentration in moles of metabolite per kilogram of tissue 
water 
[𝐻2𝑂]molal Water concentration in moles of water per kilogram of tissue water == 
55.49 moles/kg 
[𝑀]molar Metabolite concentration in moles of metabolite per litre of tissue water 
[𝐻2𝑂]molar  Water concentration in moles of water per litre of tissue water 
𝑑𝐺𝑀 Water density of grey matter 
𝑑𝑊𝑀 Water density of white matter 
𝑓𝐺𝑀 Volume fraction of gray matter inside the MRS voxel 
𝑓𝑊𝑀 Volume fraction of white matter inside the MRS voxel 
𝑓𝐶𝑆𝐹 Volume fraction of cerebrospinal fluid inside the MRS voxel  
𝑓𝐺𝑀𝐻2𝑂 Water mole fraction in gray matter 
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𝑓𝑊𝑀𝐻2𝑂 Water mole fraction in white matter 
𝑓𝐶𝑆𝐹𝐻2𝑂 Water mole fraction incerebrospinal fluid 
𝑆𝑀𝑜𝑏𝑠 Observed metabolite signal intensity in the presence of relaxation 
𝑆𝐻2𝑂𝑜𝑏𝑠 Observed water signal intensity in the presence of relaxation 
TR Repetition time 
TE1 First PRESS echo period 
TE2 Second PRESS echo period 
𝑅𝐻2𝑂𝐺𝑀 Relaxation scaling factor for water in gray matter 
𝑅𝐻2𝑂𝑊𝑀 Relaxation scaling factor for water in white matter 
𝑅𝐻2𝑂𝐶𝑆𝐹 Relaxation scaling factor for water in cerebrospinal fluid 
𝑅𝑀 Relaxation scaling factor for tissue metabolite signal 
[𝑀]𝐺𝑀 [𝑀]𝑊𝑀⁄  Assumed ratio of grey matter to white matter metabolite concentrations 
𝑅𝑀𝐺𝑀  Relaxation scaling factor for metabolite in grey matter 
𝑅𝑀𝑊𝑀  Relaxation scaling factor for metabolite in white matter 
B1 Radiofrequency field 
tCr Total Creatine 
Cr Creatine 
PCr Phosphocreatine 
tCho Total Choline 
GPC Glycerophosphocholine 
PCh Phosphocholine 
tNAA Total N-acetylaspartate 
NAA N-acetylaspartate 
NAAG N-acetylaspartylglutamate 
 
 
